Cervical Dystonia – Executive Insights – Cervical Dystonia | Executive Insights | US/EU5/China
Cervical dystonia (CD), is a rare neurological disorder that mostly affects middle-aged adults, with an average age of symptom onset of 50 years. Given the rarity of the condition and symptomatic similarities with other neurological conditions, CD is often misdiagnosed, thereby delaying appropriate treatment. The CD market is generally well served by several marketed botulinum toxins ([BoNTs]; e.g., AbbVie / Allergan’s Botox), which comprise the current standard of care in CD treatment in the United States, EU5, and China. Owing to the clinical benefits provided by entrenched BoNTs, the CD pipeline is relatively sparse and lacks variation / novelty but does portend the potential launch of biosimilars in future. For current and emerging players in this space, understanding the drivers, limiters, unmet needs, and remaining opportunities in this competitive market will be critical.
Questions Answered
- What is the diagnosed prevalence of CD in the different regions under study?
- What is the patient journey in CD, and how are patients treated today? Which BoNTs are preferred, and what factors influence drug choice?
- According to interviewed KOLs, what are the top unmet needs in the treatment of CD? What will be the potential impact of emerging BoNTs?
- What are the strengths, weaknesses, drivers, and constrainers of the CD market?
Product Description: Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Geographies: United States, EU5, China.
Primary research: 8 interviews with neurologists in February 2022.
Key companies covered: AbbVie, Ipsen, Merz Pharma, Supernus, Revance Therapeutics, Aeon Biopharma
Key drugs covered: Botox, Dysport, Xeomin, Myobloc, daxibotulinumtoxinA (DAXI, RT-002), ABP-450, onabotulinumtoxinA biosimilar
Isha Dutta, B.Tech., is an analyst on the CNS/Ophthalmology team at Clarivate. Prior to joining Clarivate, she was a senior analyst on the life sciences teams at Evalueserve and Course5 Intelligence. She also worked on oncology ad-hoc projects and competitive intelligence at Prescient Healthcare. She holds a bachelor’s degree in biomedical engineering from Bharti Vidyapeeth College of Engineering in Pune, India.
Prashant Kumar, M.P.H., Epidemiologist. Prior to joining the company, he coordinated various public health projects focused on tuberculosis, COVID, and malnutrition. He also has experience working in the health insurance domain in India, where he was involved in claims data analytics and stakeholder management. He holds an M.P.H specializing in epidemiology from the Tata Institute of Social Sciences in Mumbai.